Hepatocellular Carcinoma Interpreting the Evidence to Improve Clinical Outcomes
Credit(s): 1.00 (60 min)
Release Date: Jan 26, 2021
Expiration Date: Jan 26, 2022
CME / AMA PRA Category 1 Credit™
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide, and rates are increasing each year. The majority of HCC is diagnosed in advanced stages, where potentially curative therapy is ineffective, and outcomes are poor. In recent years, several targeted therapies and immunotherapies have emerged that have drastically changed outcomes in advanced HCC.
This program will cover current and emerging treatment options for advanced HCC, how to make patient-personalized treatment decisions, and how to manage treatment emergent adverse events to ensure optimal outcomes.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This activity is supported by an educational grant from Bayer US.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.